Combined hormone therapy and radiation therapy for locally advanced prostate cancer

Critical Reviews in Oncology/Hematology

Volumn 84, Issue SUPPL. 1, 2012, Pages e30-e34

  Bolla, M ^a,b   Laramas, M ^a,b  

^a HÔPITAL MICHALLON   (France)

^b Association of Radiotherapy and Oncology of the Mediterranean arEa   (France)

Author keywords

External irradiation; Hormonal treatment; Locally advanced prostate cancer

Indexed keywords

CYPROTERONE ACETATE; FLUTAMIDE; GONADORELIN AGONIST; GOSERELIN; TRIPTORELIN;

ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; DRUG EFFICACY; GLEASON SCORE; HUMAN; LONG TERM CARE; NONHUMAN; ORCHIECTOMY; OVERALL SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW; SHORT COURSE THERAPY; THERAPY EFFECT;

EID: 84871692357     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2010.11.003     Document Type: Review

References (30)

1. Scardino P.T., Abbas F., Adolfson J. Management of localized and regional diseases. Prostate cancer: the 3rd international consultation on prostate cancer 2003, 219-247. Health Publications, Paris. K. Denis, G. Bartsch, S. Khoury, M. Murai, A. Partin (Eds.).
2. Huggins C., Stevens R.E., Hodges C.V. Studies on prostatic cancer. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 1941, 43:209-243.
3. Schröder F.H. What is new in endocrine therapy of prostatic cancer? EORTC Genitourinary Group Monograph 7. Prostate cancer and testicular cancer 1990, 45-52. Wiley-Liss, New York. D.W.W. Newling, W.G. Jones (Eds.).
4. Parmar H., Philipps R.H., Lightman S.L., Edwards L., Allen L., Schally A.V. Randomised controlled study of orchidectomy vs long-acting D-Trp-6-LHRH microcapsules in advanced prostatic carcinoma. Lancet 1985, 2(8466):1201-1205.
5. Bagshaw M.A., Cox R.S., Ray G.R. Status of radiation treatment of prostate cancer at Stanford University. NCI Monogr 1988, (7):47-60.
6. Hanks G.E., Corn B.W., Lee W.R., Hunt M., Hanlon A., Schultheiss T.E. External beam irradiation of prostate cancer. Conformal treatment techniques and outcomes for the 1990. Cancer 1995, 75(S7):1972-1977.
7. Zelefsky M.J., Yamada Y., Kollmeier M.A., Shippy A.M., Nedelka M.A. Long-term outcome following three-dimensional conformal/intensity-modulated external-beam radiotherapy for clinical stage T3 prostate cancer. Eur Urol 2008, 53(Jun (6)):1172-1179.
8. Zietman A.L., Prince E.A., Nakfoor B.M., Park J.J. Androgen deprivation and radiation therapy: sequencing studies using the Shionogi in vivo tumor system. Int J Radiat Oncol Biol Phys 1997, 38(5):1067-1070.
9. Joon D.L., Hasegawa M., Sikes C., et al. Supraadditive apoptotic response of R3327-G rat prostate tumors to androgen ablation and radiation. Int J Radiat Oncol Biol Phys 1997, 38(5):1071-1077.
10. Kaminski J.M., Hanlon A.L., Joon D.L., Meistrich M., Hachem P., Pollack A. Effect of sequencing of androgen deprivation and radiotherapy on prostate cancer growth. Int J Radiat Oncol Biol Phys 2003, 57(1):24-28.
11. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002, 360(9327):103-106.
12. Bolla M., van Tienhoven G., de Reijke T.M., et al. Concomitant and adjuvant androgen deprivation (ADT) with external beam irradiation (RT) for locally advanced prostate cancer: 6 months versus 3 years ADT: results of the randomized EORTC Phase III trial 22,961. J Clin Oncol 2007, 25(18S):5014.
13. Lawton C.A., Winter K., Murray K., et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001, 49(4):937-946.
14. Pilepich M.V., Winter K., Lawton C.A., et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma: long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005, 61(Apr (5)):1285-1290.
15. Pilepich M.V., Winter K., John M.J., et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001, 50(Aug (5)):1243-1252.
16. Roach M., Bae K., Speight J., et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol 2008, 26(4):585-591.
17. Denham J.W., Steigler A., Lamb D.S., et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 2005, 6(Nov (11)):841-850.
18. Roach M., DeSilvio M., Lawton C., et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 2003, 21(10):1904-1911.
19. Widmark A., Klepp O., Solberg A., et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 2009, 373(Jan (9660)):301-308.
20. Hanks G.E., Pajak T.F., Porter A., et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003, 21(21):3972-3978.
21. Horwitz E.M., Bae K., Hanks G.E., et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008, 26(15):2497-2504.
22. Bolla M., de Reijke T.M., Van Tienhoven G., et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009, 360(Jun (24)):2516-2527.
23. Kuban D.A., Tucker S.L., Dong L., et al. Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008, 70(1):67-74.
24. Zapatero A., Valcarcel F., Calvo F.A., et al. Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study. J Clin Oncol 2005, 23(27):6561-6568.
25. Pommier P., Chabaud S., Lagrange J.L., et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J Clin Oncol 2007, 25(34):5366-5373.
26. Petrylak D.P., Tangen C.M., Hussain M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004, 351(15):1513-1520.
27. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 351(15):1502-1512.
28. Bolla M., Hannoun-Levi J.M., Ferrero J.M., et al. Concurrent and adjuvant docetaxel with three-dimensional conformal radiation therapy plus androgen deprivation for high-risk prostate cancer: preliminary results of a multicentre phase II trial. Radiation Oncol 2010, 97:312-317.
29. Kumar P., Perrotti M., Weiss R., et al. Phase I trial of weekly docetaxel with concurrent three-dimensional conformal radiation therapy in the treatment of unfavorable localized adenocarcinoma of the prostate. J Clin Oncol 2004, 22(10):1909-1915.
30. Heidenreich A., Aus G., Bolla M., et al. EAU guidelines on prostate cancer. Eur Urol 2008, 53(1):68-80.